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Abstract
Background: Immobilized recombinant perlecan domain I (PlnDI) binds and modulates the activity of heparin-
binding growth factors, in vitro. However, activities for PlnDI, in solution, have not been reported. In this study, we
assessed the ability of soluble forms to modulate vascular endothelial growth factor-165 (VEGF165) enhanced
capillary tube-like formation, and VEGF receptor-2 phosphorylation of human bone marrow endothelial cells,
in vitro.
Results: In solution, PlnDI binds VEGF165 in a heparan sulfate and pH dependent manner. Capillary tube-like
formation is enhanced by exogenous PlnDI; however, PlnDI/VEGF165 mixtures combine to enhance formation
beyond that stimulated by either PlnDI or VEGF165 alone. PlnDI also stimulates VEGF receptor-2 phosphorylation,
and mixtures of PlnDI/VEGF165 reduce the time required for peak VEGF receptor-2 phosphorylation (Tyr-951), and
increase Akt phosphorylation. PlnDI binds both immobilized neuropilin-1 and VEGF receptor-2, but has a greater
affinity for neuropilin-1. PlnDI binding to neuropilin-1, but not to VEGF receptor-2 is dependent upon the heparan
sulfate chains adorning PlnDI. Interestingly, the presence of VEGF165 but not VEGF121 significantly enhances PlnDI
binding to Neuropilin-1 and VEGF receptor-2.
Conclusions: Our observations suggest soluble forms of PlnDI are biologically active. Moreover, PlnDI heparan
sulfate chains alone or together with VEGF165 can enhance VEGFR-2 signaling and angiogenic events, in vitro.W e
propose PlnDI liberated during basement membrane or extracellular matrix turnover may have similar activities,
in vivo.
Background
Perlecan, a heparan sulfate proteoglycan with preferred
localization to vascular basement membranes, is com-
prised of a ~480 kDa protein core with five distinct
domains (I - V). Domains II-V share structural homo-
logies with other protein modules [1]. In contrast,
N-terminal domain I (PlnDI) is structurally unique. As a
~22 kDa protein core, PlnDI contains 172 amino acid
residues that give rise to a sperm protein, enterokinase
and agrin (SEA) module localized downstream of three
Ser-Asp-Gly motifs that serve as glycosaminoglycan
(GAG) attachment sites [2,3].
Through the chondroitin and heparan sulfate GAG
chains attached to domain I, perlecan functions as a
ligand reservoir for storage, release, and protection of
heparin-binding growth factors (reviewed by Whitelock
et al., 2008). These interactions allow perlecan to modu-
late a range of biological functions, including angiogen-
esis (reviewed by Bix and Iozzo, 2008)[4]. Recent studies
suggest immobilized forms of perlecan and PlnDI bind
VEGF165 to coordinate developmental angiogenesis by
modulating VEGF165/VEGFR-2 signaling [5,6]. However,
a role for soluble forms of PlnDI and the mechanism(s)
by which it modulates VEGF165/VEGFR-2 signaling is
unclear.
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through two receptors [7], VEGFR-1 or fms-like tyrosine
kinase 1 [8] and VEGFR-2, also known as kinase domain
receptor, and fetal liver kinase 1 [9,10]. Although
VEGFR-1 exhibits higher binding affinity for VEGFs,
VEGFR-2 dominates VEGF induced mitogenic and
angiogenic responses on endothelial cells [11,12].
VEGFR-2 signaling is enhanced by interactions with co-
receptors such as heparin/heparan sulfate and Neuropi-
lin 1 (NRP-1) [13]. In addition, VEGF binding to
VEGFR-2 and NRP-1 is enhanced by exogenous heparin
[14,15]. Although the natural cell surface and basement
membrane polysaccharide, in vivo, is heparan sulfate,
not heparin, few cell surface or extracellular HSPGs
have been shown to modulate VEGF/VEGFR interac-
tions [6,16].
Herein, we tested the hypothesis that soluble forms of
recombinant PlnDI bind and increase VEGF165/VEGFR-
2 interactions on human bone marrow endothelial cells,
in vitro. Observations from this investigation suggests
soluble forms of recombinant PlnDI are biologically
active and capable of interacting with components of
the VEGFR-2 signaling complex, enhance activity and
downstream signaling related to endothelial cell angio-
genic processes.
Results
Purification and biochemical characterization of PlnDI
Recombinant PlnDI was purified from conditioned
media of HEK 293 EBNA clones as reported previously
[17], and further enriched by passage through a Sephar-
ose CL-6B column. This additional step removed high
molecular weight contaminants secreted into the serum
free media (i.e., full length perlecan). Aliquots of the
eluted product were subsequently analyzed by SDS-
PAGE and Western blotting to identify the GAG chain
composition and preparation purity.
In Coomassie blue stained SDS-PAGE gels, undigested
samples displayed a broad band between ~45-117 kDa (Fig-
ure 1A, lane 1); whereas aliquots pre-treated with a hepari-
nase cocktail yielded a distinct band at ~36 kDa, with a
broad band between 55 -71 kDa (Figure 1A, lane 2). Chon-
droitinase ABC pre-digestion yielded a distinct band at ~33
kDa and broad band between 45 -117 kDa (Figure 1A, lane
3). Pre-digestion with both GAG lyases yielded a single
band at 33 kDa (Figure 1A, arrow lane 4). The additional
bands appearing in Figure 1A, lanes 2-4, represent BSA (j,
~66 kDa), chondroitinase ABC (δ, ~100 kDa), and hepari-
nases I (a,~ 4 3k D a ) ,I I( b,~ 8 4k D a ) ,a n dI I I( g,~ 7 0k D a ) .
In Alcian blue stained SDS-PAGE gels, undigested
samples displayed a broad band between ~45-117 kDa
Figure 1 SDS-PAGE and Western blot analysis of PlnDI. (A) Coomassie blue staining; (B) Alcian blue staining: lane 1, undigested PlnDI; lane 2,
heparinase cocktail treated PlnDI; lane 3, chondroitinase ABC treated PlnDI; lane 4 heparinase cocktail and chondroitinase ABC treated PlnDI. (C)
Western blot analysis with PlnDI and (D) heparan sulfate stub (3G10) specific antibodies respectively: Lane 1, undigested PlnDI; lane 2, heparinase
cocktail and chondroitinase ABC treated PlnDI. Heparinase cocktail is a mixture of heparinases I, II, and III. Arrows indicate the protein core of
PlnDI released after heparinase cocktail and chondroitinase ABC digestion. a,b,g,δ, j indicate the migration positions of heparinases I, II, III,
chondroitinase ABC, and BSA respectively. Bracket in panel C denotes immunoreactive products released following incomplete digestion.
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cocktail yielded a broad band between ~50-100 kDa
(Figure 1B, lane 2). Chondroitinase ABC pre-digestion
yielded a broad band between ~50-84 kDa (Figure 1B,
lane 3). Pre-digestion with both GAG lyases abolished
the majority staining.
The presence of PlnDI was confirmed by Western
blotting using anti-PlnDI specific antibodies (CSI-0071)
and antibodies (3G10) to anti-Δ-heparan sulfate that
recognize heparan sulfate neo-epitopes, generated fol-
lowing heparinase cleavage (arrow Figure 1C and 1D).
Neither antibody recognized undigested products; how-
ever, anti-PlnDI antibodies recognized partially digested
products (bracket in Figure 1C, lane 2) and both antibo-
dies recognize a distinct band at 33 kDa (arrow, Figure
1C and 1D). The 33 kDa band reflects the domain I
core protein adorned with GAG chain linkage residues
following heparinase digestion.
Biochemical analysis of PlnDI suggests a protein and
uronic acid content of 49% and 37%, respectively
(Table 1). Hexosamine (monosaccharide) composi-
tional analysis revealed PlnDI GAGs are composed
predominantly of galactosamine (60%) relative to glu-
cosamine (40%) (Table 1). The disaccharide composi-
tion of purified PlnDI revealed 6-sulfated disaccharide
as the major Δdi-CS with lesser amounts of nonsul-
fated and 4-sulfated disaccharides (Table 2). The major
Δdi-HS derived from PlnDI was nonsulfated and Δdi-
S1 with considerable, but lesser amounts of Δdi-S2,- 6 -
sulfated, -N-sulfated, and -triS disaccharides (Table 2).
The HS GAG chains on PlnDI contain approximately
3 fold more 6-O- than 2-O-sulfation.
VEGF165 binds to PlnDI in a heparan sulfate dependent
manner
To identify requirement(s) for VEGF165 binding to
PlnDI, both solid and solution phase binding assays
were performed. In solid phase binding assays, immobi-
lized PlnDI binds VEGF165 in a heparan sulfate depen-
dent manner (Figure 2). Heparinase cocktail treatment
of PlnDI, prior to immobilization on nitrocellulose,
reduced VEGF165 binding by ~75% (Figure 2). In con-
trast, pre-digestion with chondroitinase ABC did not
alter VEGF165 binding. Studies with the PlnDI protein
core, prepared following digestion with a mixture of
both enzymes, suggest VEGF165 poorly binds this region.
VEGF antibodies do not bind immobilized PlnDI (Figure
2). In competitive inhibition assays, heparin [0.25 μg/ml]
prevented ~80% of VEGF165 binding to PlnDI (Figure 2).
In solution, requirements for VEGF165 binding to
PlnDI were similar, but the capacity of binding demon-
strated pH dependence (Figure 3A). When the pH of
solution was reduced from 8.0 to 7.0 then 6.0, VEGF165
binding was reduced by 50% and 80%, respectively (Fig-
ure 3A). To identify VEGF165 specific binding, the back-
ground binding of VEGF165 to nitrocellulose was
subtracted from total bound to PlnDI [18]. Employing
this approach, PlnDI-HS chains account for nearly all
VEGF165 binding, and the presence of CS chains masks
VEGF165 interaction with HS (Figure 3B). In panel B,
neutral pH was chosen to more closely reflect tissue cul-
ture conditions of subsequent experiments.
PlnDI modulation of VEGF165 bio-activity
T oi d e n t i f yar o l ef o rP l n D Ii nm o d u l a t i n gV E G F 165
activity in vitro, human bone marrow endothelial cells
were employed in two independent assays: 1) VEGF165-
enhanced capillary tube-like formation; 2) VEGF165-
enhanced phosphorylation of VEGFR-2. In capillary
tube-like formation assays, the ability of bone marrow
endothelial cells to form tube-like structures in the pre-
sence of exogenous VEGF165 +/- PlnDI was quantified.
Under serum free conditions, the addition of soluble
VEGF165 (positive control) and PlnDI demonstrated
dose dependent increases in lengths of tube-like struc-
tures formed (Figure 4A-B and 1F). Optimal concentra-
tions for VEGF165 [20 ng/ml] and PlnDI [12.5 μg/ml]
increased tube-like formation 35% and 24%, respectively.
Studies employing PlnDI, pre-treated with either
chondroitinase ABC and/or a heparinase cocktail sug-
gests the ability of PlnDI to enhance tube-like formation
is HS chain dependent (Figure 4C). Moreover, PlnDI
activity is further enhanced when its CS chains are
removed. Interestingly, PlnDI/VEGF165 mixtures com-
bine to enhance tube-like formation 16% relative to
VEGF165 alone (Figure 4D). The synergy between PlnDI
and VEGF165 is PlnDI-HS chain dependent (Figure 4D).
PlnDI protein core/VEGF165 mixtures produce tube-like
structures indifferent from those by VEGF165 alone.
Unexpectedly, heparin/VEGF165 mixtures do not syner-
gize in this system (Figure 4E).
Since the presence of endogenous cell surface HS
complicates the studies above, experiments employing
bone marrow endothelial cells without cell surface HS
were performed. Under these conditions, VEGF165 and
PlnDI enhance tube-like formation (Figure 5); however,
PlnDI/VEGF165 mixtures did not combine to further
enhance the lengths of tube-like structures. Subsequent
dose response studies suggested elevated concentrations
of VEGF165 and PlnDI are required for maximal activity.
Increasing PlnDI concentration two fold [25.0 μg/ml]
Table 1 Biochemical composition of PlnDI
Composition (% dry weight) Hexosamine (% mol)
Sample Protein Uronic acid GalN GlcN
PlnDI 49 (0.37) 37 (0.29) 60 (0.87) 40 (0.88)
Data are presented as the mean of three independent experiments ± (SEM).
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dependent manner (Figure 5).
Because the role of HS in heparin-binding growth fac-
tor activity may involve interactions between HS, ligand,
and cell surface receptors, the ability of PlnDI-HS to
modulate VEGF165-induced VEGFR-2 tyrosine phos-
phorylation was investigated by Western blot using
VEGFR-2 (Tyr-951) specific antibodies. VEGFR-2 phos-
phorylation at Tyr-951 results in recruitment of several
adapter proteins whose subsequent downstream signal-
ing supports endothelial cell survival and migration [19].
To perform these studies, we employed bone marrow
endothelial cells whose cell surface HS were first
removed by exposure to heparinases. Under these condi-
tions, the exogenous addition of PlnDI and VEGF165
(positive control) enhanced VEGFR-2 phosphorylation
at Tyr-951 (Figure 6A-B). The signal intensity of phos-
phorylation increased over time, peaked after ten min-
utes, then returned to control levels after 20 minutes
(Figure 6A-B). The addition of PlnDI, adorned with only
HS chains, enhances Tyr-951 phosphorylation ~3 fold
relative to intact PlnDI (Figure 6C). Studies employing
PlnDI preparations pre-treated with mixtures of chon-
droitinase ABC and heparinase enzymes did not com-
pletely attenuate phosphorylation (Figure 6C). Heparin
addition (positive control) also enhanced VEGFR-2
phosphorylation (Figure 6C).
Relative to either alone, PlnDI/VEGF165 mixtures sti-
mulate peak phosphorylation after only 2.5 minutes
(Figure 7A vs. 6A-B). To identify the role of PlnDI-HS
in modulating VEGF165 induced VEGFR-2 phosphoryla-
tion at Tyr-951, PlnDI preparations adorned with either
CS, HS, or without GAGs were pre-mixed with
VEGF165. The absence of HS chains on PlnDI reduced
the signal intensity of phosphorylation 43% (Figure 7B).
In contrast, preparations decorated only with HS chains
enhance the signal intensity of phosphorylation ~3 fold
(Figure 7B). The absence of CS and HS chains did not
completely reduce the intensity of phosphorylation rela-
tive to control (VEGF165).
To determine if PlnDI/VEGF165 enhanced VEGFR-2
phosphorylation also promotes downstream signaling,
blots were stripped then re-probed with antibodies spe-
cific for total and phosphorylated forms of Akt. PlnDI/
VEGF165 mixtures enhance the signal intensity of phos-
phorylated Akt ~4 fold, relative to VEGF165 alone (Fig-
ure 7C), and ~40% of this activity is PlnDI-HS chain
dependent.
Since PlnDI may modulate phosphorylation via direct
interactions with VEGFR-2 or a candidate co-receptor,
we performed binding studies with immobilized recom-
binant VEGFR-2 and NRP-1. PlnDI binds VEGFR-2 and
NRP-1 (Figure 8A-B); however, a higher percentage of
PlnDI binds NRP-1. The presence of VEGF165 but not
VEGF121 (negative control) enhances PlnDI binding to
VEGFR-2 (27%) and NRP-1 (13%). The presence of
heparin [1 μg/ml] reduces PlnDI binding to NRP-1
more than 60%. In contrast, PlnDI binding to VEGFR-2
was poorly competed away by heparin (Figure 8A-B).
Discussion
For the first time, we have characterized the ability of
recombinant PlnDI to bind VEGF165 and modulate its
angiogenic activity, in vitro. We have shown that soluble
forms of PlnDI are capable of modulating VEGFR-2
phosphorylation, as well as VEGF165-induced phosphor-
ylation of VEGFR-2, and that the heparan sulfate glyco-
saminoglycan chains adorning PlnDI are important for
these activities. Together, our observations suggest solu-
ble forms of PlnDI may form and/or stabilize a complex
between VEGF165, NRP-1, and VEGFR-2 to enhance
angiogenic events and VEGFR-2 signaling in human
bone marrow endothelial cells (summarized in Figure 9).
Table 2 Disaccharide composition of Chondroitin and Heparan sulfate chains of PlnDI
Chondroitin sulfate (% mol) Heparan sulfate (% mol)
Sample Δdi-0S Δdi-4S Δdi-6S Δdi-0S Δdi-NS Δdi-6S Δdi-S1 Δdi-S2 Δdi-triS
PlnDI 34 (0.88) 28 (0.88) 38 (1.45) 31 (1.15) 2 (0.88) 9 (1.76) 40 (1.73) 15 (1.45) 3 (1.09)
Data are presented as the mean of three independent experiments ± (SEM).
Figure 2 Immunoblot analysis of VEGF165 binding to
immobilized PlnDI. PlnDI, undigested or pre-digested with a
heparinase cocktail +/- chondroitinase ABC were immobilized on
nitrocellulose and incubated with VEGF165. Bound VEGF165 was
detected with VEGF specific monoclonal antibodies. Horizontal bars
represent the densitometric scanning of slots outlined in
rectangular boxes. Data are presented as mean density values (DV)
of triplicate determinations ± SEM. () different from PlnDI+VEGF165;
(θ), different from PlnDI+Hepase+VEGF165. p < 0.05.
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of PlnDI employed in the present investigation was
enhanced by passage through a Sepharose CL-6B col-
umn. SDS-PAGE, Western blot and monosaccharide
analysis suggest the molecular weight and GAG chain
composition of PlnDI are similar to species previously
characterized [20,21]. Moreover, these observations pre-
dict our preparation contains at least two species of
PlnDI: one adorning predominately CS and the other
predominately HS chains. Interestingly, the CS and HS
disaccharide composition of PlnDI reported herein is
different from species recently characterized by White-
lock et al. [22], as well as that reported for full length
perlecan purified from bovine rib growth plate cartilage,
HUAEC and RT101 cell lines [23-25]. These differences
could be due to: 1) cell culture conditions; 2)
approaches for purification; and 3) approaches employed
for disaccharide analysis. Regardless, since fewer 4-sul-
fated CS residues and more 2-sulfated and 6-sulfated
HS residues were identified it is reasonable to conclude
that the function of PlnDI employed herein is distinct
from forms previously reported. Indeed, subtle variations
in HS substructure profoundly affect heparin-binding
growth factor and receptor interactions, and thus the
activity of perlecan [26-28].
While the role(s) of HS chains on perlecan have been
most widely investigated with regard to regulation of
FGF-2 activity [29,30], few studies have reported on per-
lecan-VEGF165 interactions [5,6,22]. Moreover, the GAG
modifications required specifically for perlecan-VEGF165
interactions have not been described. Nevertheless, stu-
dies with heparin/HS suggest 2-O-a n d6 - O- sulfation is
important for VEGF binding and activity [31-33].
Although the abundance of 2-O-a n d6 -O-sulfation on
Figure 3 VEGF165 binding to PlnDI in solution is pH dependent. PlnDI pre-incubated with VEGF165 in 25 mM HEPES (pH 6.0, 7.0, or 8.0) was
immobilized on nitrocellulose. VEGF165 bound to PlnDI was detected with VEGF specific monoclonal antibodies. (A) pH dependent binding of
VEGF165 to PlnDI. (B) The requirement of CS and HS chains for VEGF165 binding to PlnDI (pH 7.0). Data are presented as mean specific density
values (DV) of triplicate determinations ± SEM. Specific binding was determined by subtracting the background binding of VEGF165 to
nitrocellulose from total bound. (*) different from pH 8.0; (**) different from pH 7.0; () different from PlnDI+VEGF165;( θ), different from PlnDI
+Hepase+VEGF165. p < 0.05.
Figure 4 Exogenous PlnDI enhances capillary tube-like formation. Human bone marrow endothelial cells were seeded in 96 well plates pre-
coated with growth factor reduced Matrigel and treated with PlnDI pre-incubated +/- VEGF165. Tube length quantification was performed after
18 h on fixed cells, stained with SYTO13. Effect of VEGF165 (A), and PlnDI (B) dose on capillary tube-like formation. (C) PlnDI [12.5 μg/ml]
enhanced tube-like formation: Requirement of CS and HS chains. (D) PlnDI/VEGF165 enhanced tube-like formation: Requirement of CS and HS
chains on PlnDI. (E) Effect of heparin/VEGF165 mixtures on capillary tube-like formation. (F) Representative images of tube-like formation in panel
A. Data are presented as mean lengths of nine areas from triplicate determinations ± SEM. (*) different from media; (ψ) different from VEGF165 at
5, 10 and 80 ng; (π) different from PlnDI 6 and 25 μg; (δ) different from PlnDI; (g) different from VEGF165. p < 0.05.
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with VEGF165, a correlation between VEGF165 affinity
and abundance of a particular disaccharide or the over-
all level of HS sulfation has not been observed [31].
Thus, growth factor binding is likely determined by HS
domain organization (i.e., length of sulfation and transi-
tion domains, as well as their placement along the
chain). Since HS chains on recombinant PlnDI are likely
to be short (8-10 kDa) relative to those on tumor-
derived perlecan (30-70kDa) [21,34,35], we predict 48
residues comprise a single HS chain on PlnDI (based on
the molecular weight of repeating units of glucuronic
acid and N-acetylglucosamine). Moreover, since six or
seven oligosaccharide residues are sufficient to fully
occupy the HS binding site for VEGF165 [31], we further
p r e d i c tt h a ts i xV E G F 165 binding sites (maximally) may
be available on each HS chain attached to PlnDI.
The HS dependent binding of VEGF165 to immobi-
lized PlnDI described herein is consistent with recent
reports [5,6]. In contrast, a new communication has
reported PlnDI does not bind immobilized VEGF165
[36]. We suspect the concentration and/or the disac-
charide composition of PlnDI employed therein may
account for the contrasting observations. Our studies
with PlnDI in solution suggest VEGF165 binding to
PlnDI in solution is not only HS but pH dependent.
The marked reduction in VEGF165 binding to PlnDI
under acidic conditions, a novel observation, is consis-
tent with previous publications describing the attenua-
tion of VEGF165 binding with low concentrations of
heparin under acidic conditions, and its potentiation at
neutral pH [14,37].
To identify the ability of soluble, exogenous PlnDI to
modulate VEGF165 activity, in vitro, tube-like formation
studies were performed with human bone marrow
endothelial cells seeded on growth factor reduced (GFR)
Matrigel. We hypothesized that PlnDI/VEGF165 mix-
tures would enhance the lengths of tube-like structures
formed over VEGF165 alone. While our observations
support this hypothesis, we were surprised that PlnDI
addition, alone, also enhanced the length of tube-like
structures. Given our experimental approach, the
enhancement of tube-like formation by soluble, exogen-
ous, PlnDI may also reflect interactions with other
matrix molecules (i.e., fibronectin and laminin) and
heparin-binding growth factors present in GFR Matrigel
reported to interact with PlnDI [38]. This possibility,
however, should not discount the ability of exogenous
PlnDI to interact directly with human bone marrow
endothelial cells, or the possibility that the presence of
heparin-binding molecules and growth factors may even
mask the full activity of PlnDI.
Interestingly, under conditions where bone marrow
endothelial cells were pre-treated with a heparinase
cocktail, the additive effect of PlnDI/VEGF165 mixtures
on tube-like formation was not observed unless the con-
centration of PlnDI was increased two fold. While these
observations suggest PlnDI-HS chains can modulate
VEGF165 activity, in vitro, heparin/VEGF165 mixtures
(positive control [14,32]), did yield similar results. We
remain puzzled by this observation since heparin/
VEGF165 mixtures combine to enhance VEGFR-2 phos-
phorylation, suggesting heparin is active in our system.
At the cellular/receptor level, we analyzed VEGFR-2
auto-phosphorylation to identify requirements for PlnDI
modulation of VEGF165 activity, in vitro. While both
VEGFR-1 and VEGFR-2 contribute to VEGF induced
signals, VEGFR-2 dominates VEGF induced mitogenic
and angiogenic responses in endothelial cells [11,12]. Of
the six tyrosine phosphorylation sites identified on the
intracellular domain of VEGFR-2, we report on one
associated with endothelial cell survival and migration
[39]. Together, our observations suggest exogenous
soluble PlnDI, alone, can stimulate VEGFR-2 phosphor-
ylation at Tyr-951. Moreover, PlnDI fragments harbor-
ing only HS chains further enhance VEGFR-2
phosphorylation, suggesting the presence of CS chains
masks activity. These studies importantly extend those
recently reported for full length perlecan [6] by demon-
strating delivery of PlnDI or co-delivery with VEGF165
are sufficient to enhance VEGFR-2 phosphorylation, and
promote downstream signaling (i.e., increased Akt phos-
phorylation). Given our approach (i.e., the use of cells in
suspension), our observations suggest PlnDI/VEGF165
Figure 5 In the absence of cell surface heparan sulfate
increased PlnDI concentrations restore synergy with VEGF165.
Human bone marrow endothelial cells, in suspension, were treated
with a heparinase cocktail, washed, then incubated with PlnDI [12.5
μg/ml] +/- VEGF165 [20 ng/ml] for 30 minutes prior to seeding in
wells pre-coated with growth factor reduced Matrigel. After 18 h
cells were fixed, stained with SYTO13, and tube length quantified.
Both PlnDI and VEGF165 enhance capillary tube-like formation. A two
fold increase in PlnDI concentration [25 μg/ml] is required for
synergy with VEGF165. Data are presented as the mean lengths from
nine areas of triplicate determinations ± SEM. (*) different from
media; (g) different from VEGF165. p < 0.05.
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Page 6 of 13Figure 6 PlnDI stimulates VEGFR-2 (Tyr-951) phosphorylation. Human bone marrow endothelial cells without cell surface HS were
incubated with VEGF165 or PlnDI for 0, 2, 5, 10 and 20 minutes. Cell lysates were analyzed for VEGFR-2 phosphorylation by Western blot using
anti-phospho and total VEGFR-2 tyrosine residue 951 specific antibodies. Time dependant increase in VEGFR-2 phosphorylation induced by: (A)
VEGF165 and (B) PlnDI. (C) PlnDI induced VEGFR-2 phosphorylation: Requirement for CS and HS chains. Exogenous heparin served as a positive
control and GAPDH as loading control. Horizontal bars represent the densitometric scanning of bands outlined in rectangular boxes. Data are
presented as the mean density values (DV) from triplicate determinations ± SEM. (*) different from 0 min or media. (δ) different from PlnDI.
p < 0.05.
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Page 7 of 13Figure 7 PlnDI/VEGF165 mixtures enhance VEGFR-2 (Tyr-951) phosphorylation. Human bone marrow endothelial cells without cell surface
HS were incubated with PlnDI/VEGF165 mixtures for either 0, 2, 5, 10, or 20 min. Cell lysates were analyzed for VEGFR-2 (A and B) or Akt (C)
phosphorylation by Western blot using anti-phospho and total VEGFR-2 (tyrosine residue 951) and Akt specific antibodies. (B) PlnDI/VEGF165
enhanced VEGFR-2 phosphorylation (at min 2.5): Requirement of CS and HS chains on PlnDI. Horizontal bars represent the densitometric
scanning of bands outlined in rectangular boxes. GAPDH was assessed as a loading control. Data are presented as the mean of three
independent experiments ± SEM. (*) different from 0 min; (g) different from VEGF165;( ) different from PlnDI+VEGF165. p < 0.05.
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phosphorylation) of human bone marrow endothelial
cells, in vitro. Consistent with this conclusion, our
unpublished observations suggest VEGFR-2 phosphory-
lation at Tyr-1175 and Tyr 1214, and phosphorylation
of p38 MAPK, Erk1/2 (events associated with endothe-
lial cell proliferative and migratory states) [39], are
unaltered.
Finally, to determine if PlnDI has the capacity to bind
and modulate the activity of VEGFR-2 directly, we per-
formed PlnDI binding studies against immobilized
VEGFR-2, and NRP-1. Outcomes from these studies sug-
gest PlnDI-HS chains, similar to heparin/HS, harbor the
capacity to interact with VEGFRs and co-receptors
[15,32,40], and enhance VEGFR-2 signaling [41]. We sus-
pect PlnDI-HS chain binding to NRP-1 occurs via its
heparin binding domain [15]. In contrast, PlnDI binding
to VEGFR-2 is less dependent on HS chains. Heparin con-
centrations up to [100 μg/ml] did not appreciably alter
binding (unpublished observations). Interestingly, the pre-
sence of VEGF165 enhances PlnDI binding to VEGFR-2,
suggesting the formation of a complex between PlnDI/
VEGF165/VEGFR-2 is possible. Our observations also sug-
gest that modulation of VEGFR-2 signaling by PlnDI may
involve complex interactions with more than one ligand.
Conclusion
The findings presented herein demonstrate exogenous,
soluble, recombinant PlnDI is sufficient to bind and
modulate the activity of the VEGFR-2 signaling complex
via HS interactions, in vitro. Moreover, PlnDI may have
activities independent of those with heparin-binding
growth factors in supporting tube-like formation, in vitro.
Figure 9 provides a simplified visual depiction of how
PlnDI may impact angiogenic events in the absence or
presence of VEGF165. PlnDI unbound or bound to
VEGF165 is liberated via cleavage within its SEA module
[42] or the single immunoglobulin G-like region of
domain II [43,44] during matrix turnover, wound healing,
or disease progression. In the absence of VEGF165, PlnDI-
H Sm a yb i n dt oN R P - 1 ,V E G F R - 2 ,o rs u p p o r tc o m p l e x
formation with both to signal downstream angiogenic
events. When VEGF165 is present PlnDI interactions with
NRP-1 and VEGFR-2 are optimized, leading to enhanced
downstream signaling and angiogenesis.
Methods
Materials
Recombinant human VEGF165,V E G F R - 2 ,N R P - 1 ,a n d
anti-VEGF165 monoclonal antibodies were procured
f r o mR & Ds y s t e m s ,I n c .( M i n n e a p o l i s ,M N ) .G r o w t h
factor reduced Matrigel was purchased from BD Bios-
ciences (San Jose, CA). Goat polyclonal antibodies to
GAPDH were purchased from Genscript (Piscataway,
Figure 8 PlnDI binds NRP-1 and VEGFR-2. Recombinant NRP-1
and VEGFR-2 coated plates were incubated with PlnDI +/- VEGF165
or VEGF121. PlnDI binding was detected and quantified using an
ELISA based approach that employed anti-PlnDI specific antibodies.
For competitive inhibition assays, PlnDI was pre-incubated with
heparin [1 μg/ml]. (A) PlnDI binding to VEGFR-2. (B) PlnDI binding to
NRP-1. Data are presented as a percentage of total bound. (*)
different from PlnDI. p < 0.05.
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Page 9 of 13NJ). Rabbit polyclonal antibodies for phospho- and
total- VEGFR-2, and Akt were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling
(Danvers, MA), respectively. Anti-Perlecan domain I
monoclonal antibodies (CSI 001-71) were purchased
from the Antibody Shop (Denmark). Anti-Perlecan
domain IV antibodies were purchased from Millipore
(Temecula, CA). Heparin, heparinase I, II and III and
protease free chondroitinase ABC were purchased from
Sigma (St. Louis, MO). Heparitinase II enzyme, 3G10
antibodies, and unsaturated heparan/heparin-disacchar-
ide standards were purchased from Seikagaku Corp
(Japan).
Cell Culture
Human bone marrow endothelial cells, provided by Dr.
G Almeida-Porada (University of Nevada, Reno, [45]),
were cultured in M199 media supplemented with
endothelial cell growth supplement (R&D systems Inc,
Minneapolis, MN), 10% (v/v) heat-inactivated FBS, 1%
(v/v) penicillin/streptomycin, 2 mM glutamax and
heparin (15 U/ml). Cells were sub-cultured when 80-
90% confluent using 0.05% (v/v) trypsin/EDTA. All cul-
tures were maintained at 37°C in a humidified 5% CO2
atmosphere.
Sepharose CL-6B enrichment of Recombinant PlnDI
Recombinant perlecan domain I (PlnDI) was prepared as
described previously [17]. PlnDI was enriched by passage
through a Sepharose CL-6B column (1 × 50 cm), pre-
equilibrated with 50 mM Tris-HCl buffer, pH 8.6 con-
taining 6 M guanidine-HCl and 0.5 M NaCl. Fractions
were assayed for uronic acid by carbazole method [46],
and protein by micro BCA assay (Pierce, Rockford, IL).
PlnDI purity was assessed by SDS-PAGE (i.e., Alcian blue
and Coomassie blue staining) and Western blotting (see
below).
Western Blotting
PlnDI (25 μg), untreated or pre-digested with heparinase
cocktail (mixture of heparinases I, II and III, 2.5 Sigma
units each) and/or chondroitinase ABC, were electro-
phoresed on 3-8% Tris-acetate gels (Invitrogen, CA),
then transferred to nitrocellulose. Membranes were
probed with anti-PlnDI monoclonal antibodies diluted
(1:200) in phosphate buffered saline (PBS) with 0.1% (v/
v) Tween-20 (PBST), containing 3% (w/v) BSA. Primary
antibodies were detected with anti-mouse IgG secondary
antibodies conjugated to peroxidase and visualized by
incubation with enhanced chemiluminescence reagent
(ECL, GE Healthcare), and exposure to film.
Chondroitinase ABC and Heparinase digestion
For chondroitinase ABC digestion PlnDI (25 μg) was
incubated with chondroitinase ABC (20 mU) in 25 μlo f
100 mM/L Tris-HCl, pH 8.0, containing 30 mM/L
sodium acetate and 0.01% (w/v) BSA at 37°C for 5
hours. For heparinase digestion, PlnDI was incubated
Figure 9 Model: PlnDI interactions with the VEGFR-2 signaling complex. N-terminal domain I of perlecan, unbound or bound to VEGF165,
liberated by proteolytic cleavage (scissors) during extracellular matrix turnover stimulates angiogenesis by direct interactions with: 1) NRP-1;2 )
VEGFR-2; and 3) NRP-1 and VEGFR-2. PlnDI may enhance VEGF165 stimulated pro-angiogenic events by stabilizing NRP-1/VEGF165/VEGFR-2
interactions.
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Page 10 of 13with a heparinase cocktail in 25 μl of PBS containing
4m MC a C l 2 and protease inhibitors for 12 hours at
room temperature.
Immunoassays
Solid phase binding assays were performed as described
previously [17]. For solution phase binding assays, PlnDI
(5 μg) untreated, or pre-digested with a heparinase
cocktail and/or chondroitinase ABC was pre-incubated
with 20 ng of VEGF165 in PBS containing 3% (w/v) BSA,
o r2 5m MH E P E Sa te i t h e rp H8 . 0 ,7 . 0 ,o r6 . 0[ 3 7 ] ,o r
50 mM Tris-HCl (pH 8.0), PBS (pH 7.0), 50 mM
sodium acetate (pH 6.0) for 1 hr at room temperature.
Samples were subsequently blotted onto nitrocellulose,
and blocked. Bound VEGF165 was detected with anti-
VEGF165 antibodies (1 μg/ml in 3% (w/v) BSA in PBST).
Primary antibodies were detected with anti-mouse IgG
secondary antibodies conjugated to HRP and visualized
as described for Western blotting. Binding was quanti-
fied by densitometry and expressed as mean density
values (DV) from triplicate assays. Specific binding was
determined by subtracting VEGF165 background from
total bound [18].
Capillary Tube-like Assay
Growth factor reduced (GFR) Matrigel was added to
wells of ice-cold 96-well plates (70 μl/well) for 6 sec-
onds. Excess was removed, leaving a thin coating. Plates
were incubated for 6 minutes on ice, 20 minutes at
room temperature, and finally warmed for 20 minutes at
37°C. Bone marrow endothelial cells were seeded (6,500
cells/well) in serum free RPMI 1640 media containing
1% (w/v) penicillin/streptavidin, 2 mM glutamax without
growth supplements. After cell attachment, the media
was replaced with media containing one or more
supplements [i.e., PlnDI (12.5 μg/ml), untreated or pre-
digested with a heparinase cocktail and/or chondroiti-
nase ABC, heparin (4.0 μg/ml), VEGF165 (20 ng/ml)].
For assays conducted in the absence of cell surface
heparin sulfate, human bone marrow endothelial cells
were cultured for 15 minutes under serum free condi-
tions in RPMI 1640 media supplemented with hepari-
nase cocktail [32]. Such treatments temporarily remove
more than 95% of cell surface HS. Prior to seeding cells
were washed twice with RPMI 1640 media.
To quantify tube-like formation cells were fixed (4%
(v/v) paraformaldehyde) after 18 h, stained (SYTO13,
I n v i t r o g e n ,C A ) ,t h e np h o t o g r a p h e dw i t haS P O TC C D
camera affixed to an inverted microscope equipped for
epifluorescence. Nine random fields, representing 80%
of each well, were analyzed for three angiogenic para-
meters: average tube length (defined as three or more
cells connected lengthwise, and exceeding 100 μmi n
length; [47], number of tube-like structures, and the
number of branch points, using Image J software (NIH).
When several tube-like structures merged together or
branched, the total length was calculated as the sum of
the individual branches. All tube-like formation studies
were conducted in quadruplicate wells, and repeated at
least three times. Since the outcomes of each angiogenic
parameter were similar only average tube length is
reported. Note: All supplement concentrations employed
herein are optimal, and were determined empirically
over a broad range. As a control for enzyme activity,
assays were also conducted with supplements containing
heat inactivated chondroitinase ABC and/or heparinase
cocktail.
Receptor Phosphorylation studies
Bone marrow endothelial cells, cultured to 80% conflu-
ence, were rinsed twice with serum free media, and then
cultured for 24 hrs under serum free conditions. Cells
were pre-incubated with a heparinase cocktail to remove
cell surface heparan sulfate (as described above) then incu-
bated with serum free media containing supplements
(PlnDI, VEGFs, and heparin, as described above) for either
0, 2.5, 5, 10 or 20 minutes. After washing (ice-cold PBS),
the cells were lysed [10 mM Tris-HCl, buffer pH 7.4 con-
taining 140 mM NaCl, 0.2% (v/v) Triton X-100, 1.5 mM
EDTA, 1 mM Na3PO4, 25 mM NaF, and 1 mM Na3VO4,
protease inhibitors (Roche Diagnostics, Lewes, UK)], and
total protein concentrations determined (micro BCA
assay). For Western blotting, 30 μg of each sample was
loaded onto 7% Tris-acetate gels, electrophoresed under
reducing conditions, then transferred onto nitrocellulose.
Membranes were probed with anti-phospho-VEGFR-2
(tyrosine residue (Tyr)-951), phospho-Akt, anti total-
VEGFR-2, total-Akt, and anti-GAPDH antibodies. Primary
antibodies were detected and visualized as described for
Western blotting.
Enzyme Linked Immunosorbant Assay
Recombinant proteins (NRP-1 and VEGFR-2) were
allowed to bind overnight (4°C) in 96-well plates (100
ng/well; Maxi Sorp, Nunc). After several washes and
blocking with PBS containing 3% BSA, PlnDI (5 μg/
well) with or without VEGF121,V E G F 165, or heparin
[0.01-1000 μg/mL] was added. After 2 h, and several
washes with PBS containing 0.05% Tween 20, the plates
were incubated with anti-PlnDI antibodies (1:500 dilu-
tion) for 1 h. Primary antibodies were detected with
anti-rabbit IgG secondary antibodies conjugated to HRP
(1:8000). Each well was subsequently incubated with tet-
ramethylbenzidine (KPL; 100 μl/well) for 10 min under
gentle agitation. Color development was stopped with
50 μLo f0 . 5NH 2SO4. Binding was quantified by mea-
suring absorbance at 450 nm. Unless indicated, all incu-
bations were performed at room temperature.
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As done previously [46], PlnDI (20 μg) was hydrolyzed
with 4 M HCl at 100°C for 6 h, then dried in a Speed-
Vac. Residues were dissolved in HPLC grade water then
analyzed on a CarboPac PA1 high pH anion-exchange
column (4 × 250 mm) using Dionex BioLC HPLC
coupled to a pulse amperometric detector.
Disaccharide composition analysis of GAG chain
As done previously [48], CS disaccharides, released from
PlnDI (20 μg) following digestion with chondroitinase
ABC [(20 mU) in 50 μl of 100 mM Tris-HCl, 30 mM
NaOAc, pH 8.0, containing 0.01% (w/v) BSA at 37°C for
5 h] were analyzed by HPLC on the 4.6 × 250 mm
amine-bonded silica PA03 column. Unsaturated HS dis-
accharides released from PlnDI following digestion with
heparinase cocktail were analyzed as above. Commer-
cially prepared bovine tracheal CS disaccharide stan-
dards (ΔDi-0 S, ΔDi-4 S and ΔDi-6S), and unsaturated
heparan/heparin-disaccharide standards were used to
determine standard migration positions and for
quantitation.
Statistical analysis
All experiments were conducted in triplicate, repeated at
least three times, and analyz e db yt w o - t a i l e dp a i r e d
Student’s t-test using GraphPad Prism version 5.0 for
Windows (San Diego California USA). Differences were
considered significant at P <0 . 0 5 .A l lr e s u l t sa r ep r e -
sented as means ± standard error of the mean.
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